• 82W.DU is trading 2.99% down today at €29.16.
  • The decline follows significant insider stock sales by Hims & Hers' (82W.DU) Chief Financial Officer and Chief Medical Officer on June 18 and June 22, totaling over $1.4 million.
  • The company also faces increasing competitive pressure in the telehealth testosterone therapy market, notably after LifeMD announced an exclusive Xyosted program on June 22, which is set to launch in July.